Hong Kong-Based Aptorum Group, Aenco’s Affiliated Company and Early HealthTech Ecosystem Supporter, Has Filed for an Initial Public Offering to List on Nasdaq Global Market!
Aptorum Group (“Aptorum”), a Hong Kong-based biopharmaceutical company, and close affiliate of Aenco, has also been one of our earliest and most collaborative HealthTech partners. They continue to be a cornerstone participant within the Aenco Blockchain ecosystem and we are proud to announce this successful milestone achievement! The company, under the leadership of its co-founders, Mr. Ian Huen and Mr. Darren Lui, has connected us to a plethora of medical resources and expertise. Through Aptorum, Aenco will be able to co-develop a growing HealthTech and drug development ecosystem globally.
Aptorum is looking to raise US$30 million in its U.S. IPO, by offering 1.8 million Class A ordinary shares at a price range of $14.50 to $16.50. Its shares are expected to begin trading under the ticker symbol “APM” starting in November 2018 subject to final regulatory and exchange approval.
The company continues to further develop a portfolio of drug and device candidates and innovations, and is raising capital to drive these programmes towards human clinical trials. The therapeutic and diagnostic technologies Aptorum focuses on relate to multi-disciplinary medical fields such as neurology, infectious diseases, gastroenterology, and oncology, among others.
Aptorum is an affiliated biopharmaceutical company that exemplifies Aenco’s vision to support the constant pairing of sound science, with robust financing, for the furthering of medical innovations! Aenco will continue to expand its platform solutions and implement distributed ledger technology into real industry applications. Such applications that support impactful use cases includes applying distributed computing power to fuel drug development processes for treating diseases, as well as applying Aenco’s token economy and data communication technology to stimulate greater medical research collaboration!
For greater information about Aptorum, please visit their investor relations site here:
Other public resources referencing their offering can be found here:
Securities and Exchange Commission (“SEC”) filing:
Date: October 16, 2018